

CITATION REPORT

List of articles citing

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies

DOI: 10.1016/0002-9149(91)90944-g
American Journal of Cardiology, 1991, 67, 1295-7.

Source: <https://exaly.com/paper-pdf/22434782/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
237	Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias. 1991 , 5, 671-5		4
236	The role of beta receptor blockade in preventing sudden death. 1992 , 13, 111-120		32
235	Cumulative meta-analysis of therapeutic trials for myocardial infarction. 1992 , 327, 248-54		930
234	Secondary prevention with calcium antagonists after acute myocardial infarction. 1992 , 44 Suppl 1, 33-43		7
233	Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction. Value, limitations and implications for therapy. 1992 , 44, 336-55		8
232	Meta-analysis in clinical trials reporting: has a tool become a weapon?. <i>American Journal of Cardiology</i> , 1992 , 69, 681-6	3	30
231	A view from Europe. <i>American Journal of Cardiology</i> , 1992 , 70, 331-391	3	2
230	Usefulness of nifedipine in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992 , 69, 836-7	3	
229	Reply. <i>American Journal of Cardiology</i> , 1992 , 69, 837	3	
228	Maximizing benefits of therapies in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1993 , 72, 145G-155G	3	5
227	Are all calcium antagonists equally effective for reducing reinfarction rate?. <i>American Journal of Cardiology</i> , 1993 , 72, 818-20	3	8
226	Role of Phenylalkylamine Calcium Antagonists in the Treatment of Ischaemic Heart Disease. 1993 , 5, 177-185		
225	Nicardipine. A review of its pharmacology and therapeutic efficacy in older patients. 1993 , 3, 165-87		17
224	Nicardipine: A Widely Applicable Calcium Antagonist. 1993 , 2, 4-6		
223	Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. 1993 , 14 Suppl F, 18-25		73
222	The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. 1993 , 15, 967-78		133
221	The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. 1993 , 2, 86-100		76

220	Effects of Prophylactic Antiarrhythmic Drug Therapy in Acute Myocardial Infarction. 1993 , 270, 1589		331
219	1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.. <i>Hypertension</i> , 1993 , 22, 392-403	8.5	160
218	Secondary Prevention After Myocardial Infarction. 1993 , 153, 285		9
217	Memorandum from a Who/Ish Meeting. 1993 , 15, 1363-1395		17
216	Development of a multiaction beta blocker. Scientific challenges and regulatory needs. 1993 , 82 Suppl 3, 50-8		1
215	Oil and Water? Economic Advantage and Biomedical Progress Do Not Mix Well in a Government Guidelines Committee. 1994 , 7, 877-885		8
214	Risks and benefits of antiarrhythmic therapy. 1994 , 331, 785-91		101
213	Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction. 1994 , 8 Suppl 3, 543-7		8
212	Long-term survival and use of antihypertensive medications in older persons. 1995 , 43, 1191-7		190
211	The role of calcium antagonists in ischaemic heart disease. 1995 , 16 Suppl H, 19-24		15
210	Are antianginal drugs effective in secondary prevention after myocardial infarction?. 1995 , 16 Suppl E, 38-40		
209	Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives?. 1995 , 43, 1309-10		9
208	Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995 , 75, 4E-9E	3	7
207	ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. 1995 , 9 Suppl 3, 503-7		5
206	Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. 1995 , 123, 888-9		36
205	Section Review: Cardiovascular & Renal: Developments in antiarrhythmic drugs: An overview. 1995 , 4, 1101-1128		3
204	Should Dihydropyridines Be Used as First-Line Drugs in the Treatment of Hypertension?. 1995 , 155, 2157		15
203	The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies. 1995 , 274, 620		491

202	The effects of calcium antagonists after PTCA. 1995 , 16 Suppl H, 9-12	8
201	Trends in Pharmacologic Management of Hypertension in the United States. 1995 , 155, 829	80
200	Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass. 1995 , 8, 712-8	8
199	[Introduction to meta-analytic methodology]. 1995 , 16, 536-46	5
198	Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. 1996 , 28, 7-11	76
197	A comparative review of the adverse effects of calcium antagonists. 1996 , 15, 91-106	38
196	Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. 1996 , 9, 975-104S; discussion 108S-109S	18
195	ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 1996 , 28, 1328-428	871
194	Sustained-release verapamil and trandolapril, alone and in combination, in the treatment of obese hypertensive patients: a double-blind pilot study. 1996 , 57, 990-997	6
193	Management of acute myocardial infarction in the elderly. 1996 , 8, 358-77	13
192	Calcium antagonists in the elderly. A risk-benefit analysis. 1996 , 9, 24-36	17
191	Anti-ischaemic therapy during the follow-up phase of acute coronary syndromes. Is there a role for calcium channel blockers?. 1996 , 52 Suppl 4, 20-30	2
190	Current drug treatment and treatment patterns with antihypertensive drugs. 1996 , 52, 1-16	21
189	Cost-effectiveness of hypertension treatment. 1996 , 18, 399-413	9
188	Therapy for Acute Myocardial Infarction. 1996 , 12, 141-168	18
187	Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSYS). 1996 , 17, 76-81	180
186	Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. 1996 , 17, 43-63	120
185	The unnecessary controversy. 1996 , 17, 1142-7	25

184	Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). <i>American Journal of Cardiology</i> , 1996 , 78, 153-7	3	5
183	Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. <i>American Journal of Cardiology</i> , 1996 , 78, 203-207	3	39
182	A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). <i>American Journal of Cardiology</i> , 1996 , 77, 365-9	3	66
181	Verapamil following uncomplicated myocardial infarction: promising, but not proven. <i>American Journal of Cardiology</i> , 1996 , 77, 421-2	3	16
180	Prognosis of patients with stable angina pectoris on antianginal drug therapy. <i>American Journal of Cardiology</i> , 1996 , 77, 6D-15D	3	13
179	Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. <i>American Journal of Cardiology</i> , 1996 , 77, 22D-25D	3	11
178	Prognosis of patients with coronary artery disease on treatment with calcium channel antagonists. Introduction. <i>American Journal of Cardiology</i> , 1996 , 77, 1D-2D	3	
177	Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase. The Calcium Antagonist in Reperfusion Study (CARES) Group. <i>American Journal of Cardiology</i> , 1996 , 78, 1049-52	3	13
176	Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine. <i>American Journal of Cardiology</i> , 1996 , 78, 13-8	3	63
175	Safety of calcium antagonists: dissecting the evidence. <i>American Journal of Cardiology</i> , 1996 , 78, 19-23	3	37
174	Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. 1996 , 38, 273-90		43
173	1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?. 1996 , 10, 397-402		1
172	Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. 1996 , 10, 463-6		8
171	Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. 1996 , 18, 569-79		10
170	Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993. 1996 , 17, 1199-206		28
169	Angina pectoris in patients with a history of myocardial infarction. 1996 , 17 Suppl G, 25-9		35
168	Health Outcomes Associated With Antihypertensive Therapies Used as First-Line AgentsA Systematic Review and Meta-analysis. 1997 , 277, 739		457
167	Pharmacological differences between calcium antagonists. 1997 , 18 Suppl A, A71-9		42

166	Major differences among the three classes of calcium antagonists. 1997 , 18 Suppl A, A56-70	31
165	Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. 1997 , 18 Suppl A, A92-104	17
164	Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad hoc subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. 1997 , 6, 134-46	2
163	Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. 1997 , 15, 87-91	29
162	Angiotensin converting enzyme inhibitor-calcium antagonist combination. 1997 , 15, S109-S117	8
161	Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition. 1997 , 15, S3-7	15
160	Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. 1997 , 81, 1319-33	10
159	Antiarrhythmic therapies for the prevention of sudden cardiac death. 1997 , 54, 235-52	21
158	Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). 1997 , 135, 109-18	11
157	Safety of heart rate-lowering calcium antagonists: lessons from controlled trials. 1997 , 134, S21-4	2
156	Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. 1997 , 133, 550-7	31
155	Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. 1997 , 58, 331-342	7
154	Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. 1997 , 29, 1414-21	48
153	Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group. 1997 , 19, 1368-78	11
152	Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. 1997 , 19 Suppl A, 39-52	18
151	The calcium channel blocker controversy in 1997. 1997 , 27, 330-5	4
150	Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. 1997 , 11, 131-6	13
149	"Cardioprotection"--not all calcium antagonists are created equal: second round. <i>American Journal of Cardiology</i> , 1997 , 79, 788-9	3 5

148	Interrelationship between cellular calcium homeostasis and free radical generation in myocardial reperfusion injury. 1997 , 104, 65-85		53
147	Comparison of verapamil versus felodipine on heart rate variability after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1997 , 79, 564-9	3	17
146	Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. 1997 , 11, 5-16		16
145	Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. <i>Pharmacoepidemiology and Drug Safety</i> , 1997 , 6 Suppl 3, S51-9	2.6	32
144	Long-term mortality follow-up of hospital survivors of a myocardial infarction randomized to nifedipine in the SPRINT study. Secondary Prevention Reinfarction Israeli Nifedipine Trial. 1998 , 12, 171-6		5
143	Verapamil use in patients with cardiovascular disease: an overview of randomized trials. 1998 , 21, 633-41		61
142	Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. 1998 , 54, 203-8		17
141	Treatment for high blood pressure: evidence and practice. 1998 , 2, 5-6		
140	Outcome with calcium channel antagonists after myocardial infarction: a community-based study. 1998 , 31, 111-7		16
139	Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. 1998 , 135, 406-13		11
138	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. 1998 , 140, 199-270		422
137	Influence of Vasodilator Drugs on Perioperative Blood Pressure. 1998 , 2, 204-221		
136	The many faces of rickets. 1998 , 338, 681-2		7
135	Calcium-channel blockers for hypertension--uncertainty continues. 1998 , 338, 679-81		76
134	The evolving relation between humans and Mycobacterium tuberculosis. 1998 , 338, 677-8		87
133	Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. 1998 , 19, 1434-503		757
132	Management of older persons after myocardial infarction. 1998 , 46, 1459-68		10
131	Therapy for acute myocardial infarction in older persons. 1998 , 46, 1302-7		10

130	Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can we do about It?. 1999 , 19, 138-143		50
129	Use of Meta-Analysis to Evaluate Medical Questions of Interest: An Application to Studies of Secondary Prevention of Acute Myocardial Infarction. 1999 , 33, 1161-1171		3
128	Calcium antagonists "some agents lower blood pressure and still put the heart at risk"?. 1999 , 21, 823-34		1
127	Editorials: A Cautionary Note for Nephrologists: Is It Time to Abandon the Use of Dihydropyridine Calcium Channel Blockers?. 1999 , 12, 137-139		1
126	Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. 1999 , 13, 61-7		8
125	Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction. 1999 , 13, 127-35		9
124	The effect of verapamil on left ventricular remodelling and diastolic function after acute myocardial infarction (the Verapamil Infarction Study on Remodelling and Relaxation--VISOR). 1999 , 13, 315-24		5
123	The World Health Organization--International Society of Hypertension Blood Pressure Lowering Treatment TrialistsPCollaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. 1999 , 1, 346-56		6
122	Antiischemic therapy in patients with coronary heart disease living in long-term care. Systematic Assessment of Geriatric Drug Use by Epidemiology (SAGE) Group. 1999 , 19, 627-34		14
121	Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995. <i>American Journal of Cardiology</i> , 1999 , 84, 632-8	3	4
120	An application of meta-analysis techniques in the evaluation of adverse experiences with antihypertensive agents. <i>Pharmacoepidemiology and Drug Safety</i> , 1999 , 8, 169-77	2.6	3
119	An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment TrialistsPCollaboration. 1999 , 21, 517-29		12
118	Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. 1999 , 137, 1094-9		36
117	Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. 1999 , 137, 79-92		38
116	Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. 1999 , 106, 499-505		32
115	Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction. 1999 , 47, 512-7		7
114	Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction. 2000 , 11, 331-8		4
113	Nifedipine and mortality risk in the elderly: relevance of drug formulation, dose and duration. <i>Pharmacoepidemiology and Drug Safety</i> , 2000 , 9, 11-23	2.6	10

112	The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology hot topic? <i>Pharmacoepidemiology and Drug Safety</i> , 2000 , 9, 25-35	2.6	4
111	Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. 2000 , 43, 171-96		82
110	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). <i>American Journal of Cardiology</i> , 2000 , 86, 24-9	3	5
109	Management of patients with myocardial infarction and hypertension. 2000 , 21, 1125-34		2
108	Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. 2000 , 21, 1406-32		245
107	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment TrialistsPCollaboration. 2000 , 356, 1955-64		1249
106	Heart failure complicating acute myocardial infarction. 2000 , 16, 535-48		3
105	Drug treatment of elderly patients with acute myocardial infarction: practical recommendations. 2001 , 18, 807-18		6
104	Coronary benefits of calcium antagonist therapy for patients with hypertension. 2001 , 16, 349-55		17
103	Verapamil revisited: a transition in novel drug delivery systems and outcomes. 2001 , 3, 55-62		34
102	Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. 2001 , 161, 1145-58		41
101	Prior calcium channel blockade and short-term survival following acute myocardial infarction. 2001 , 15, 487-92		1
100	Task Force on Sudden Cardiac Death of the European Society of Cardiology. 2001 , 22, 1374-450		520
99	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Hypertension</i> , 2001 , 37, 19-27	8.5	87
98	Treatment of the elderly post-myocardial infarction patient. 2001 , 10, 316-22, 376		2
97	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2002 , 23, 1809-40		580
96	Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. 2002 , 39, 315-22		59
95	l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. 2002 , 45, 175-81		29

94	Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. 2002 , 16, 819-27	15
93	Clinical trial experience around the globe: focus on calcium-channel blockers. 2003 , 26, 117-11	20
92	[Differential therapy with calcium antagonists]. 2003 , 28, 754-63	5
91	[Acute coronary syndrome: ST-segment elevation infarct]. 2003 , 153, 434-49	1
90	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, S1-S78	44
89	The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients. 2003 , 5, 337-44	1
88	Clinical use of nifedipine GITS in the treatment of hypertension: an overview. 2003 , 4, 95-106	8
87	Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. 2003 , 24, 28-66	946
86	Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. <i>Hypertension</i> , 2003 , 41, 1006-9	8.5 13
85	Management of the elderly person after myocardial infarction. 2004 , 59, 1173-85	8
84	Triggered activity due to delayed afterdepolarizations in sites of focal origin of ischemic ventricular tachycardia. 2004 , 287, H2078-84	40
83	Calcium antagonists. 2004 , 47, 34-57	93
82	Calcium antagonists and beta-blockers: impact on cardiovascular and cerebrovascular events. 2004 , 6, 18-27	3
81	The safety and use of short-acting nifedipine in hospitalized hypertensive children. 2004 , 19, 644-50	31
80	[Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation]. 2004 , 93, 324-41	99
79	Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. 2004 , 147, 1047-53	30
78	[Acute coronary syndromes with ST-segment elevation]. 2004 , 33, 618-22	
77	Syndromes coronariens aigus sans sus-décalage du segment ST en médecine d'urgence. 2005 , 2, 1-10	2

76	[Acute coronary syndrome in the prehospital phase]. 2005 , 54, 957-74	2
75	MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATION. 2005 , 1, 62-95	2
74	Contemporary management of acute coronary syndrome. 2005 , 81, 217-22	2
73	Tratamiento farmacológico del infarto agudo de miocardio. Fibrinólisis. Criterios de respuesta y seguimiento. 2005 , 9, 2653-2661	
72	Syndromes coronariens aigus sans sus-décalage du segment ST en médecine d'urgence. 2005 , 2, 205-218	2
71	Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. 2006 , 144, 884-93	515
70	Síndrome coronario agudo sin elevación del segmento ST en medicina de urgencias. 2006 , 32, 1-11	
69	Chitosan Beads as a New Gastroretentive System of Verapamil. 2006 , 74, 175-188	22
68	Antagonistes du calcium. 2006 , 1, 1-8	
67	Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. 2006 , 96, 515-22	41
66	Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica. 2006 , 6, 31A-40A	
65	Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiomyocytes. 2007 , 19, 213-24	53
64	Pharmacologic and Therapeutic Considerations in Hypertension Therapy With Calcium Channel Blockers: Focus on Verapamil. 2007 , 9, 1-22	6
63	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1598-660	1438
62	Heart-failure-complicating acute myocardial infarction. 2007 , 23, 123-39	1
61	Heart failure-complicating acute myocardial infarction. 2007 , 3, 465-75	2
60	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2007 , 60, 1070.e1-1070.e80	14
59	Treatment after myocardial infarction. 2007 , 33, 39-47	3

58	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. 2008 , 29, 2909-45	1774
57	Impact of cilazapril on fibrinolytic system in hypertensive patients. 2008 , 19, 101-5	2
56	NHG-Standaard Atriumfibrilleren. 2009 , 52, 646-663	9
55	Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. 2009 , 122, 356-65	28
54	[Not Available]. 2009 , 62, 293.e1-293.e47	5
53	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. 2012 , 33, 2569-619	3978
52	Newer Pharmaceutical Agents for STEMI Interventions. 2012 , 1, 429-440	
51	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. 2013 , 66, 53.e1-53.e46	17
50	Long-term care and prevention. 2013 , 98-115	
49	Coronary Artery Spasm: Part I Clinical Aspect. 2014 , 1-21	
48	Drug Treatment of Stable Coronary Artery Disease. 2016 , 167-177	0
47	Influenza vaccine as a coronary intervention for prevention of myocardial infarction. 2016 , 102, 1953-1956	79
46	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. 2016 , 24,	4
45	Rat Models of Ventricular Fibrillation Following Acute Myocardial Infarction. 2017 , 22, 514-528	8
44	Pharmacological blockade of small conductance Ca-activated K channels by ICA reduces arrhythmic load in rats with acute myocardial infarction. <i>Pflugers Archiv European Journal of Physiology</i> , 2017 , 469, 739-750	4.6 10
43	Heart Failure Complicating Acute Myocardial Infarction. 2017 , 13, 513-525	4
42	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. 2017 , 70, 1082.e1-1082.e61	35
41	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. 2017 , 19, D151-D162	0

40 References. **2018**, 694-840

39	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). 2018 , 39, 119-177		4237
38	Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction. 2020 , 26, 539-551		3
37	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4449	1.3	22
36	Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 181-264	1.2	7
35	Mechanisms underlying pathological Ca handling in diseases of the heart. <i>Pflugers Archiv European Journal of Physiology</i> , 2021 , 473, 331-347	4.6	5
34	Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. <i>Pharmacoepidemiology and Drug Safety</i> , 1997 , 6, S51-S59	2.6	4
33	NHG-Standaard Atriumfibrilleren. 2011 , 313-339		0
32	The Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). 2005 , 325-339		2
31	Calcium Antagonists. 2005 , 683-704		6
30	Acute Coronary Syndromes. 2009 , 535-596		9
29	Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 29, 692-6	3.1	24
28	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, S1-S78		145
27	Surgical bleeding: unexpected effect of a calcium antagonist. <i>BMJ: British Medical Journal</i> , 1995 , 310, 776-7		65
26	Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?. <i>BMJ: British Medical Journal</i> , 1996 , 312, 1143-5		18
25	Nifedipine and mortality. Grave defects in the dossier. <i>Circulation</i> , 1995 , 92, 1068-73	16.7	119
24	Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation?. <i>Circulation</i> , 1995 , 92, 1079-82	16.7	65
23	Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. <i>Circulation</i> , 1995 , 92, 1326-31	16.7	768

22	Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. <i>Hypertension</i> , 1997 , 29, 537-8	8.5	24
21	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. <i>Russian Journal of Cardiology</i> , 2020 , 25, 4103	1.3	59
20	Therapy of Acute Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008 , 293-326		2
19	Management of the Older Patient After Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008 , 327-350		2
18	Calcium Antagonists. 2000 , 148-166		
17	Non-Antithrombotic Treatment of Acute Coronary Syndromes: Role of Beta-Blockers, Calcium Channel Blockers, and Nitrates. 2002 , 141-155		
16	Koronarinsuffizienz und Herzinfarkt. 2003 , 3-29		
15	Klinik der koronaren Herzerkrankung II: Akute Koronarsyndrome. 2004 , 497-529		
14	Beta Blockers, Calcium Channel Blockers, Ranolazine, Nitrates, and Nitric Oxide Donors. 2011 , 253-260		
13	Anti-ischemic pharmacotherapy in patients with established coronary artery disease. 2012 , 278-286		
12	Efficacy and Safety of Calcium Antagonists as Antianginal Agents. <i>Developments in Cardiovascular Medicine</i> , 1994 , 201-211		
11	Cardioprotection by Calcium Antagonists: Myocardial Ischemia and Secondary Prevention. <i>Medical Science Symposia Series</i> , 1995 , 119-128		
10	Therapie mit Calciumantagonisten: Erhöhtes Risiko für Myokardinfarkt und Mortalität. 1996 , 365-370		1
9	Klinik der koronaren Herzerkrankung II: Akuter Herzinfarkt. 1996 , 679-724		
8	Calciumantagonisten bei chronischer Herzinsuffizienz. 1996 , 311-323		
7	Calciumantagonisten bei koronarer Herzkrankheit. 1996 , 121-160		
6	Klinik der koronaren Herzerkrankung III: Der Herzinfarkt im chronischen Stadium. 1996 , 725-770		
5	Adrenergic Blockers, Calcium Channel Blockers, and Nitrates. <i>Contemporary Cardiology</i> , 1999 , 337-356	0.1	

4 Coronary Artery Spasm: Clinical Aspect. **2015**, 1827-1844

3 Koronarinsuffizienz und Herzinfarkt. **2005**, 3-33

2 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. *Bulletin of the World Health Organization*, **1993**, 71, 503-17 8.2 22

1 THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). **2009**, 12-18 0